During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral ...
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 ...
Kailera Therapeutics is advancing a pipeline of obesity drugs, led by the GLP-1/GIP dual agonist ribupatide, which the ...
In this bonus episode, BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel take a ...
The draft guidance supports the agency’s new pathway designed to speed up the development of custom gene therapies.
Some 30% of clinical trials that are mandated to report their findings have not posted results to clinicaltrials.gov, the ...
With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a ...
By closing the Universal Cells Seattle location, Astellas is reportedly consolidating cell therapy, gene therapy and oncology ...
The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis ...
In addition, fear and apprehension about genetic sampling and invasive tissue collection need to be taken into account and ...
Trastuzumab pamirtecan, being developed under a 2023 partnership between BioNTech and DualityBio, elicited a 44.1% overall ...
The FDA has gained a reputation during the past year for being inconsistently flexible, particularly when it comes to rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results